Last Update 16:47
Sunday, 21 July 2019

UK-based pharmaceutical firm to purchase Egypt's EPCI

Multinational Hikma Pharmaceutical to buy Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI)for $22.2 million, company announces Wednesday

Ahram Online, Wednesday 9 Jan 2013
Multinational Hikma Pharmaceutical
Multinational Hikma Pharmaceutical (Photo: Reuters)
Share/Bookmark
Views: 3092
Share/Bookmark
Views: 3092

Hikma Pharmaceutical plans to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI), according to a Wednesday press release issued by the UK-based multinational.

The company said it would pay LE142.4 million (approximately $22.2 million) for the Egyptian pharmaceutical firm.

Hikma attributed its decision to buy EPCI to the fact that the Egyptian pharmaceutical market represents one of the largest and fastest growing markets in the Middle East/North Africa region.

"Since we entered the Egyptian market in 2007, we have been rapidly growing our presence," Hikma CEO Said Darwazah said. "This acquisition will further accelerate that growth, expanding our product portfolio and adding additional manufacturing capacity and technologies."

IMS Health, a leading provider of information, services and technology for the healthcare industry, estimates that the private retail market in Egypt – currently valued at around $2.3 billion – grew by 10.6 per cent in the 12 months to June 2012.

Hikma, which is listed on the London Stock Exchange, first entered the Egyptian pharmaceutical market in 2007 through its acquisition of Alkan Pharma in Egypt, now Hikma-Egypt.

Hikma-Egypt is currently the seventeenth largest pharmaceutical manufacturer in the country, with an estimated market share of 1.6 per cent.

Short link:

 

Email
 
Name
 
Comment's
Title
 
Comment
Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code
  • We will not publish comments which contain rude or abusive language, libelous statements, slander and personal attacks against any person/s.
  • We will not publish comments which contain racist remarks or any kind of racial or religious incitement against any group of people, in Egypt or outside it.
  • We welcome criticism of our reports and articles but we will not publish personal attacks, slander or fabrications directed against our reporters and contributing writers.
  • We reserve the right to correct, when at all possible, obvious errors in spelling and grammar. However, due to time and staffing constraints such corrections will not be made across the board or on a regular basis.
Latest

© 2010 Ahram Online.